These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 10699900)
1. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900 [TBL] [Abstract][Full Text] [Related]
2. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related]
3. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514 [TBL] [Abstract][Full Text] [Related]
4. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy. Amornmarn R; Bui MM; Prempree TB; Masood S Ann Clin Lab Sci; 2000 Jan; 30(1):33-40. PubMed ID: 10678581 [TBL] [Abstract][Full Text] [Related]
5. Negative margin status improves local control in conservatively managed breast cancer patients. Obedian E; Haffty BG Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736 [TBL] [Abstract][Full Text] [Related]
7. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
9. Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings. Fisher B; Wickerham DL; Deutsch M; Anderson S; Redmond C; Fisher ER Semin Surg Oncol; 1992; 8(3):153-60. PubMed ID: 1496226 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708 [TBL] [Abstract][Full Text] [Related]
13. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480 [TBL] [Abstract][Full Text] [Related]
15. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731 [TBL] [Abstract][Full Text] [Related]
16. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma. Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262 [TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical detection and prognostic significance of p53 in the primary tumor of breast carcinoma patients]. Beck T; Weller E; Weikel W; Brumm C; Wilkens C; Knapstein PG Geburtshilfe Frauenheilkd; 1995 May; 55(5):252-7. PubMed ID: 7607381 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Parikh RR; Housman D; Yang Q; Toppmeyer D; Wilson LD; Haffty BG Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1056-63. PubMed ID: 18676094 [TBL] [Abstract][Full Text] [Related]
19. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Fisher ER; Anderson S; Redmond C; Fisher B Semin Surg Oncol; 1992; 8(3):161-6. PubMed ID: 1496227 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]